SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Verrica Pharmaceuticals
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 9.99% in Verrica Pharmaceuticals Inc., totaling 9,235,571 shares of common stock.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', have filed an Amendment No. 1 to Schedule 13G.
- The filing discloses their beneficial ownership of 9,235,571 shares of Common Stock, $0.0001 par value, in Verrica Pharmaceuticals Inc.
- This aggregate amount represents 9.99% of Verrica Pharmaceuticals Inc.'s outstanding common stock.
- Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC, and is also deemed to beneficially own the shares.
- Both reporting persons share voting and dispositive power over the 9,235,571 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, as certified by the reporting persons.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of a significant ownership stake. While not inherently positive or negative, a large institutional stake can be perceived as a positive signal by the market, indicating investor confidence.
Positives
- The disclosure of a significant 9.99% stake by an institutional investor like Armistice Capital and its managing member, Steven Boyd, could be viewed as a vote of confidence in Verrica Pharmaceuticals Inc.
Negatives
- The document itself does not contain any negative financial or operational information about Verrica Pharmaceuticals Inc.
Risks
- The document does not detail specific risks related to Verrica Pharmaceuticals Inc.'s operations or financial health, as it is a beneficial ownership filing.
Future Outlook
The Schedule 13G filing does not contain any forward-looking statements or guidance regarding Verrica Pharmaceuticals Inc.'s future performance or strategic direction.
Industry Context
This filing is a standard disclosure of a significant ownership stake by an investment firm in a pharmaceutical company. It does not provide broader industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Disclosure Compliance | The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11. | 03/31/2025 | This certification clarifies the passive nature of the investment, indicating that the reporting persons do not intend to exert control over Verrica Pharmaceuticals Inc. beyond potential nomination activities. |
Related Party Transactions
- Steven Boyd is the managing member of Armistice Capital, LLC, and both are reporting persons for the same beneficial ownership, indicating a related party relationship in the context of this filing.
Stakeholder Impact
- Shareholders: The disclosure of a significant 9.99% stake by an institutional investor may influence investor perception and potentially the stock price.
- Company Management: Awareness of a large, passive institutional holder may influence strategic considerations, though the filing explicitly states no intent to control.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement (beneficial ownership threshold met). |
| 05/15/2025 | Date of signature for the Schedule 13G filing by Armistice Capital, LLC and Steven Boyd. |
Keywords
Verrica Pharmaceuticals Inc., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Adviser, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.